Autres langues ADC Therapeutics SA

Actions

ADCT

CH0499880968

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:38:58 03/09/2026			Varia. 5j.	Varia. 1 janv.
1,350 ^USD	+2,27%		+25,71%	-62,61%

14/08	ADC Therapeutics : RBC pondère les risques réglementaires de LOTIS-5 face aux opportunités de LOTIS-7	MT
13/08	Transcript : ADC Therapeutics SA, Q2 2026 Earnings Call, Aug 13, 2026

Autres langues

13:16	ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
14/08	ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says
13/08	ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
06/08	ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
01/07	ADC Therapeutics Announces New Employee Inducement Grant
30/06	ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial
30/06	ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study
30/06	ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
29/06	ADC Therapeutics SA(NYSE:ADCT) added to Russell 2000 Value Benchmark
29/06	ADC Therapeutics SA(NYSE:ADCT) added to Russell Microcap Value Benchmark Index
29/06	ADC Therapeutics SA(NYSE:ADCT) added to Russell 3000E Value Benchmark
29/06	ADC Therapeutics SA(NYSE:ADCT) added to Russell 3000 Value Benchmark
29/06	ADC Therapeutics SA(NYSE:ADCT) added to Russell Small Cap Comp Value Benchmark
29/06	ADC Therapeutics SA(NYSE:ADCT) added to Russell 2500 Value Benchmark
24/06	ADC Therapeutics Cuts 17% of Workforce, Targets $10 Million in Annual Savings
24/06	ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
24/06	ADC Therapeutics SA Plans Approximately 17% Workforce Reduction
08/06	ADC Therapeutics Shares Fall After HC Wainwright Downgrade
04/06	Top Midday Decliners
04/06	ADC Therapeutics plunges after patient deaths in blood cancer drug trial
04/06	Top Premarket Decliners
03/06	ADC Therapeutics' Drug Regimen to Treat B-Cell Lymphoma Meets Primary Endpoint of Progression-Free Survival in Phase 3 Trial
03/06	ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
03/06	ADC Therapeutics Announces Topline Results From LOTIS-5 Phase 3 Confirmatory Trial Of ZYNLONTA In Combination with Rituximab In Relapsed or Refractory Diffuse Large B-Cell Lymphoma